Identification:
a. Symptoms: Sudden onset of fever, headache, nausea, vomiting, lethargy, and irritability in cases of meningococcemia; headache, nausea, vomiting, and stiff neck in cases of meningitis. A petechial rash is seen frequently. Delirium and coma are not uncommon. Fulminant cases may present with ecchymosis and shock.
b. Differential Diagnosis: Other bacterial or viral agents of meningitis and sepsis, rickettsial diseases (e.g., Rocky Mountain spotted fever), and anaphylactoid purpura.
c. Diagnosis: Positive culture or detection of N. meningitidis-specific nucleic acid from a normally sterile site, e.g., blood or cerebrospinal fluid; positive bacterial antigen test in CSF or Gram-negative diplococci in a normally sterile site. A clinical diagnosis or clinically compatible presentation, specifically clinical purpura fulminans, in the absence of laboratory confirmation, must be investigated.
3. Incubation: 2-10 days; commonly 3-4 days. h. Recent out-of-county travel.
i. Gender of sexual partners (i.e., is patient a man who has sex with men (MSM)).
j. Meningococcal vaccination history.
k. HIV status.
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CONTROL OF CASE, CONTACTS & CARRIERS
Public Health Nursing Protocol: Home visit is required -a face to face interview is required.
Refer to "Public Health Nursing Home Visit Required Algorithm" (B-73 Part IV Public Health Nursing Home Visit Protocol).
Investigate the day of report.
CASE:
Droplet precautions in addition to standard precautions until 24 hours after start of antibiotic therapy.
1. Immediate hospitalization.
If hospitalization refused, droplet precautions
until end of febrile period and until acute symptoms subside.
3. If treatment refused, patient to remain under droplet precautions until released by the PH Medical Director.
CONTACTS:
Prophylaxis: Indicated for household members, others who frequently eat or sleep in the same dwelling, childcare center contacts, and anyone having direct contact with case's oral secretions (e.g., sharing beverages or cigarettes, kissing, during resuscitation, or other activities that result in exposure to oral or nasal secretions) during the 7 days prior to onset of illness. During outbreaks, prophylaxis recommendations may be expanded.
Please consult ACDC. Prophylaxis should be given immediately and no later than 14 days after last exposure.
Rifampin: <1 month of age: 5 mg/kg by mouth every 12 hours for 2 days.
>1 month of age:
For children (1-12 years), 10 mg/kg (maximum 600 mg) every 12 hours for 2 days.
For adults: 20 mg/kg (maximum 600 mg) orally every 12 hours for 2 days. 
OUTBREAKS
A meningococcal disease outbreak is defined by the occurrence of multiple confirmed or probable primary cases of meningococcal disease of the same serogroup in a community or institution over a short period of time. This may be as few as 2 cases depending on the size of the institution or circumstance.
The population at-risk is defined as a group of persons who, in addition to close contacts, are considered to be at increased risk for N. meningitidis when compared with the risk for this disease in the general U.S. population. This group is usually defined on the basis of organizational or community affiliation.
Meningococcal vaccines may be recommended for use in control of N. meningitidis outbreaks caused by vaccine preventable serogroups (see PREVENTION-EDUCATION section).
PREVENTION-EDUCATION
1. Mass prophylaxis generally is not indicated.
2. Special attention should be given to school, institutional, and military settings. 
